Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

41P - Surufatinib plus toripalimab and chemotherapy for second-line treatment of RAS/BRAF mutant (MT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC): A single-arm, phase II study (APHRODITE)

Date

27 Jun 2024

Session

Poster Display session

Presenters

Yi Zheng

Citation

Annals of Oncology (2024) 35 (suppl_1): S1-S74. 10.1016/annonc/annonc1477

Authors

H. zhang1, L. Liu2, X. Zhu2, Y. Gao2, Z. Tong2, Q. Fu2, X. Bao2, X. Dai2, P. Zhao2, W. Fang2, Y. Zheng3

Author affiliations

  • 1 zhejiang university fisrt affliated hospital, hangzhou/CN
  • 2 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou/CN
  • 3 The First Affiliated Hospital of Zhejiang University, Hangzhou/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 41P

Background

Treatment options for patients (pts) with RAS/BRAF MT MSS mCRC are limited. Surufatinib (S, a small-molecule inhibitor targeting VEGFR-1/2/3, FGFR-1 and CSF-1R) plus toripalimab (T, a PD-1 inhibitor) has shown synergistic anti-tumor effects in solid tumor pts. This single-arm, phase II study aims to investigate the efficacy and safety of S plus T and chemotherapy in RAS/BRAF MT MSS mCRC pts who received first-line therapy.

Methods

Eligible pts (pathologically confirmed mCRC with RAS/BRAF MT and MSS, failing first-line chemotherapy) were treated with S (250mg PO QD), T (3mg/kg, IV, D1) and standard 2nd-line chemotherapy every 2 weeks until disease progression, unacceptable toxicity, or consent withdrawal. The primary endpoint was ORR (per RECIST 1.1). Secondary endpoints included DCR, PFS, OS, and safety. Simon’s two-stage optimum design was employed, only ≥4 pts reached PR/CR in 19 pts (first stage), the study would be continued.

Results

At the cutoff date of Mar 15, 2024, 16 pts were enrolled [median age 60 years, 50% male, 75% ECOG PS 0, 56.25% with liver metastases (LMs), 68.75% prior bevacizumab]. ORR was 31.25% (5/16) and DCR was 93.75% (15/16). In pts without LMs, the ORR and DCR were 42.85% and 100.0%. Median PFS (mPFS) was 7.98 months (95%CI: 4.27-11.70), with bevacizumab-pretreated pts showing longer PFS (9.23 vs 5.75 months; p=0.91). OS data were immature. The most common treatment-related adverse events (any grade; grade 3/4) were neutropenia (56.5%; 52.2%), leukopenia (56.5%; 17.4%) and diarrhea (52.2%; 17.4%). Serious adverse events were reported in 5 pts with no grade 4 SAEs occurred.

Conclusions

Combination of surufatinib with toripalimab and chemotherapy showed promising antitumor activity and encouraging survival benefits with manageable safety in the second-line treatment for RAS/BRAF mutant microsatellite stable metastatic CRC. The results warrant further investigations in a large cohort.

Clinical trial identification

NCT04653480.

Legal entity responsible for the study

The First Affiliated Hospital, Zhejiang University School of Medicine.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.